Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becotatug Vedotin With or Without ICIs in Neoadjuvant Treatment of Resectable LAHNSCC
NCT07381075Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jul 2026
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of becotatug vedotin in head and neck squamous cell carcinoma (HNSCC), sponsored by West China Hospital of Sichuan University. Started Jul 2026; status: recruiting.
02
Drugs
becotatug vedotin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07381075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07381075.